Myeloid Panel

Haemato-Oncology

09-MYP-27

NGS panel testing for myeloid malignancies (AML, MPN and MDS)

Overview

The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.

At a glance

Product Code:

09-MYP-27

Target/Genes:

Myeloid NGS panel testing for the assessment of myeloid malignancies, including acute myeloid leukaemia (AML), myeloproliferative neoplasms (MPN), and myelodysplastic syndromes (MDS). Testing may be performed using any appropriate NGS gene panel for myeloid malignancies.

Technology:

NGS, Panel testing

Sample Type:

DNA (in TE Buffer)

Submit Results In:

English, French, German, Italian, Spanish

Accredited:

No

Key Dates

Register by

01/03/2027

Samples ship

To be finalised

Survey Period

To be finalised (for exact dates, please see scheme instructions)

Final Results

To be finalised (for exact dates, please see scheme instructions)

Sample Details

Three mock clinical cases will be provided with corresponding DNA samples for analysis, interpretation and reporting.

Approximately 1.0-2.0µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Panel testing can be performed using any appropriate gene panel for myeloid malignancies. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

Send your enquiry by submitting the form

Closes in 112 days

From £545.00

Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.

Add to enquiry list
  • Submit results in 5 languages

Questions about this scheme?
Contact our team

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)